Literature DB >> 23551721

Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review.

John Doane1, Barry Stults.   

Abstract

Four patients experienced visual hallucinations that appear to have been precipitated by lisinopril. Other cases of visual hallucinations have been reported with other angiotensin-converting enzyme (ACE) inhibitors. Older patients, particularly those with a history of either dementia or mild cognitive impairment, may be at higher risk. Hallucinations resolved within 1 to 30 days after cessation of ACE inhibitors. Development of visual hallucinations after initiation of ACE inhibitors should prompt discontinuation of therapy. Visual hallucinations have been reported in one case involving an ARB. Visual hallucinations have not been associated with direct renin inhibitors. Consideration should be given to use of alternative, unrelated antihypertensive drug classes. ©2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551721      PMCID: PMC8033881          DOI: 10.1111/jch.12063

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  Visual hallucinations after quinapril.

Authors:  A Walker
Journal:  N Z Med J       Date:  1999-03-12

2.  Quinapril-associated acute psychosis in an older woman.

Authors:  M M Tarlow; A Sakaris; R Scoyni; G Wolf-Klein
Journal:  J Am Geriatr Soc       Date:  2000-11       Impact factor: 5.562

3.  Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice.

Authors:  S Takai; K Song; T Tanaka; H Okunishi; M Miyazaki
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

4.  Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study.

Authors:  T A Ala; K H Yang; J H Sung; W H Frey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-01       Impact factor: 10.154

5.  Bipolar affective symptoms associated with use of captopril and abrupt withdrawal of pargyline and propranolol.

Authors:  T McMahon
Journal:  Am J Psychiatry       Date:  1985-06       Impact factor: 18.112

6.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

7.  ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.

Authors:  Wilbert S Aronow; Jerome L Fleg; Carl J Pepine; Nancy T Artinian; George Bakris; Alan S Brown; Keith C Ferdinand; Mary Ann Forciea; William H Frishman; Cheryl Jaigobin; John B Kostis; Giuseppi Mancia; Suzanne Oparil; Eduardo Ortiz; Efrain Reisin; Michael W Rich; Douglas D Schocken; Michael A Weber; Deborah J Wesley
Journal:  J Am Coll Cardiol       Date:  2011-04-26       Impact factor: 24.094

8.  Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs.

Authors:  D W Cushman; F L Wang; W C Fung; C M Harvey; J M DeForrest
Journal:  Am J Hypertens       Date:  1989-04       Impact factor: 2.689

9.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Authors:  Clive Ballard; Maria Luisa Hanney; Megan Theodoulou; Simon Douglas; Rupert McShane; Katja Kossakowski; Randeep Gill; Edmund Juszczak; Ly-Mee Yu; Robin Jacoby
Journal:  Lancet Neurol       Date:  2009-01-08       Impact factor: 44.182

Review 10.  Angiotensin-converting enzyme inhibitors.

Authors:  Joseph L Izzo; Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-18       Impact factor: 3.738

View more
  1 in total

1.  Factors affecting hallucinations in patients with delirium.

Authors:  Masako Tachibana; Toshiya Inada; Masaru Ichida; Norio Ozaki
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.